CX1739 [CAS 1086377-48-1]

CX1739 is a low impact enhancer of AMPA-glutamate receptors (AMPARs) . CX1739 enhances long-term potentiation dose-dependently in mouse model. CX1739 also abrogates amphetamine-induced locomotor activity. CX1739 rapidly reverses opioid-induced respiratory depression. CX1739 can be studied in research for dementia, neuropsychiatric disorders, and severe complication of opiate-induced suppression of endogenous inspiratory breathing rhythms[1].

[1086377-48-1]

C13H15N3O3

261.28

O=C(C1=CC2=NON=C2C=C1)N(C)C3CCOCC3

IGluR

99.9

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature